This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/company/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/pharmgkb/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/pubchem-compound/
n20http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n4http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00832/identifier/chemspider/
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00832
rdf:type
n5:Drug
n5:description
Phensuximide is an anticonvulsant in the succinimide class. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.
n5:generalReferences
# Rankin GO, Cressey-Veneziano K, Wang RT, Brown PI: Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. J Appl Toxicol. 1986 Oct;6(5):349-56. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3772011 # CHEN G, WESTON JK, BRATTON AC Jr: Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14020499 # Ferrendelli JA, Kinscherf DA: Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol. 1979 Jun;5(6):533-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/38736
n5:group
approved
n5:indication
For the treatment of epilepsy.
n5:manufacturer
n13:271B485D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00832 n20:DB00832
dcterms:title
Phensuximide
adms:identifier
n8:PA164771230 n11:Phensuximide n12:46505695 n15:6839 n16:C07437 n17:D00508 n18:6578 n19:DB00832
n5:mechanismOfAction
Phensuximide's mechanism of action not understood, but may act in inhibitory neuronal systems that are important in the generation of the three per second rhythm. It's effects may be related to its ability to inhibit depolarization-induced accumulation of cyclic AMP and cyclic GMP in brain tissue.
n5:synonym
Fensuximida Phensuximide Milontin Phensuximidum Fensuccimide
n5:proteinBinding
21%
n5:IUPAC-Name
n6:271B4862-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4868-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4867-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4864-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4865-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4866-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4860-363D-11E5-9242-09173F13E4C5 n6:271B4878-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B487A-363D-11E5-9242-09173F13E4C5 n6:271B485E-363D-11E5-9242-09173F13E4C5 n6:271B4861-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B485F-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:N03AD02
n5:H-Bond-Acceptor-Count
n6:271B486E-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B486F-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4869-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B486A-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B486C-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B486B-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B486D-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapid and complete.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
86-34-0
n5:category
n5:Bioavailability
n6:271B4874-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4876-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4877-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B4879-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B4873-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B4872-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4875-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B4863-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B4870-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B4871-363D-11E5-9242-09173F13E4C5